Drugs and Pharmaceuticals News

Phase I/II & Confirmatory Phase II Studies

SAN MARINO, Calif., Nov. 20 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth.

Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies.

Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy.

These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems.

To learn more about Rexin-G® and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at www.epeiusbiotech.com.



NEWS SOURCE: Epeius Biotechnologies Corporation

Send2Press® is the originating wire service for this story.

PRESS RELEASE PERMALINK: http://www.send2press.com/newswire/2008-11-1120-005.shtml

For more information about this news release, contact Epeius Biotechnologies Corporation directly through their Web site found in the above press release, and NOT Send2Press.

Copyright © 2008 by Send2Press® Newswire, part of the Neotrope® News Network (California, USA). All rights reserved. License/Terms of Use: Attribution Required ("Send2Press® is the originating wire service").